Literature DB >> 23766458

JMML patient-derived iPSCs induce new hypotheses.

Rebecca J Chan1, Mervin C Yoder.   

Abstract

In this issue of Blood, Gandre-Babbe et al have, in part, overcome the obstacle of validating the molecular underpinnings of juvenile myelomonocytic leukemia (JMML) with the generation of induced pluripotent stem cells (iPSCs) from individuals with JMML.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23766458     DOI： 10.1182/blood-2013-05-500090

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  4 in total

1.  Neuroscience: From embryo mutation to adult degeneration.

Authors:  Stefan P Tarnawsky; Mervin C Yoder
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

2.  Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.

Authors:  Stefan P Tarnawsky; Momoko Yoshimoto; Lisa Deng; Rebecca J Chan; Mervin C Yoder
Journal:  Dev Dyn       Date:  2017-10-23       Impact factor: 3.780

Review 3.  Modeling cancer progression using human pluripotent stem cell-derived cells and organoids.

Authors:  Meili Zhang; J Jeya Vandana; Lauretta Lacko; Shuibing Chen
Journal:  Stem Cell Res       Date:  2020-10-27       Impact factor: 2.020

4.  Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate.

Authors:  Kazuki Taoka; Shunya Arai; Keisuke Kataoka; Masataka Hosoi; Masashi Miyauchi; Sho Yamazaki; Akira Honda; Wei Aixinjueluo; Takashi Kobayashi; Keiki Kumano; Akihide Yoshimi; Makoto Otsu; Akira Niwa; Tatsutoshi Nakahata; Hiromitsu Nakauchi; Mineo Kurokawa
Journal:  Sci Rep       Date:  2018-10-26       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.